230 related articles for article (PubMed ID: 23028181)
1. SNM 2012 image of the year.
J Nucl Med; 2012 Oct; 53(10):23N. PubMed ID: 23028181
[No Abstract] [Full Text] [Related]
2. 99mTc-tektrotyd SPECT/MRI in the diagnosis of a gastroenteropancreatic neuroendocrine tumor.
Zandieh S; Gambini JP; Haller J; Rodrigues M
Clin Nucl Med; 2012 Apr; 37(4):e84-5. PubMed ID: 22391730
[No Abstract] [Full Text] [Related]
3. Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors.
Deppen SA; Liu E; Blume JD; Clanton J; Shi C; Jones-Jackson LB; Lakhani V; Baum RP; Berlin J; Smith GT; Graham M; Sandler MP; Delbeke D; Walker RC
J Nucl Med; 2016 May; 57(5):708-14. PubMed ID: 26769865
[TBL] [Abstract][Full Text] [Related]
4. Repeated peptide receptor radiotherapy in multiple recurrences of a metastasized neuroendocrine tumor.
Brogsitter C; Zöphel K; Folprecht G; Eisenhofer G; Kotzerke J
Nuklearmedizin; 2017 Jun; 56(3):N19-N21. PubMed ID: 28358166
[No Abstract] [Full Text] [Related]
5. Impact of initial imaging with gallium-68 dotatate PET/CT on diagnosis and management of patients with neuroendocrine tumors.
Crown A; Rocha FG; Raghu P; Lin B; Funk G; Alseidi A; Hubka M; Rosales J; Lee M; Kennecke H
J Surg Oncol; 2020 Mar; 121(3):480-485. PubMed ID: 31853990
[TBL] [Abstract][Full Text] [Related]
6. Clinical Usefulness of Somatostatin Receptor Scintigraphy in Japanese Patients with Gastroenteropancreatic Neuroendocrine Tumors.
Hasegawa S; Kobayashi N; Tokuhisa M; Goto A; Takano S; Takada Y; Kaneta T; Mori R; Matsuyama R; Endo I; Yamanaka S; Nakajima A; Inoue T; Ichikawa Y
Digestion; 2017; 96(1):13-20. PubMed ID: 28609761
[TBL] [Abstract][Full Text] [Related]
7. Molecular Imaging of Gastroenteropancreatic Neuroendocrine Tumors: Current Status and Future Directions.
Deroose CM; Hindié E; Kebebew E; Goichot B; Pacak K; Taïeb D; Imperiale A
J Nucl Med; 2016 Dec; 57(12):1949-1956. PubMed ID: 27811124
[TBL] [Abstract][Full Text] [Related]
8. Gastroenteropancreatic neuroendocrine tumors: current perspectives and future challenges.
Garcia-Carbonero R
Cancer Metastasis Rev; 2014 Mar; 33(1):343-4. PubMed ID: 24357057
[No Abstract] [Full Text] [Related]
9. Is 18F-Fluorodeoxyglucose the Tracer of Choice for Functional Imaging of Neuroendocrine Tumors Grade 3? A Case Report.
Lorusso M; Inzani F; Castaldi P; Menghi R; Schinzari G; Rindi G; Rufini V
Pancreas; 2018 Apr; 47(4):e20-e22. PubMed ID: 29521949
[No Abstract] [Full Text] [Related]
10. Diffuse Bone Metastases in Pancreatic Neuroendocrine Tumor Shown on Octreoscan.
Adkins J; Lu Y
Clin Nucl Med; 2019 Mar; 44(3):257-258. PubMed ID: 30624276
[TBL] [Abstract][Full Text] [Related]
11. Endoscopic imaging in the management of gastroenteropancreatic neuroendocrine tumors.
Pellicano R; Fagoonee S; Altruda F; Bruno M; Saracco GM; De Angelis C
Minerva Endocrinol; 2016 Dec; 41(4):490-8. PubMed ID: 27600643
[TBL] [Abstract][Full Text] [Related]
12. Peptide Receptor Radionuclide Therapy in the Treatment of Neuroendocrine Tumors.
Kwekkeboom DJ; Krenning EP
Hematol Oncol Clin North Am; 2016 Feb; 30(1):179-91. PubMed ID: 26614376
[TBL] [Abstract][Full Text] [Related]
13. Does the pretherapeutic tumor SUV in 68Ga DOTATOC PET predict the absorbed dose of 177Lu octreotate?
Ezziddin S; Lohmar J; Yong-Hing CJ; Sabet A; Ahmadzadehfar H; Kukuk G; Biersack HJ; Guhlke S; Reichmann K
Clin Nucl Med; 2012 Jun; 37(6):e141-7. PubMed ID: 22614212
[TBL] [Abstract][Full Text] [Related]
14. Consensus document on the progression and treatment response criteria in gastroenteropancreatic neuroendocrine tumors.
Merino-Casabiel X; Aller J; Arbizu J; García-Figueiras R; González C; Grande E; Jiménez-Fonseca P; Sevilla MI; Capdevila J
Clin Transl Oncol; 2018 Dec; 20(12):1522-1528. PubMed ID: 29766455
[TBL] [Abstract][Full Text] [Related]
15. Aggressive gastro-entero-pancreatic neoplasms.
Coriat R
Ann Endocrinol (Paris); 2019 Jun; 80(3):185-186. PubMed ID: 31064660
[No Abstract] [Full Text] [Related]
16. Detection of somatostatin receptor subtypes 2 and 5 by somatostatin receptor scintigraphy and immunohistochemistry: clinical implications in the diagnostic and therapeutic management of gastroenteropancreatic neuroendocrine tumors.
Sclafani F; Carnaghi C; Di Tommaso L; Rodari M; Destro A; Rimassa L; Giordano L; Chiti A; Roncalli M; Santoro A
Tumori; 2011; 97(5):620-8. PubMed ID: 22158494
[TBL] [Abstract][Full Text] [Related]
17. [Gastroenteropancreatic neuroendocrine neoplasms-Heterogeneity, management and perspectives of treatment and research].
Luley K; Gebauer J; Gebauer N; Tharun L; Buchmann I; Barkhausen J; von Bubnoff N; Lindner K; Keck T; Lehnert H; Schmid SM
Internist (Berl); 2020 Aug; 61(8):875-890. PubMed ID: 32676723
[TBL] [Abstract][Full Text] [Related]
18. PRRT: Defining the paradigm shift to achieve standardization and individualization.
Bodei L; Kidd M; Baum RP; Modlin IM
J Nucl Med; 2014 Nov; 55(11):1753-6. PubMed ID: 25256058
[TBL] [Abstract][Full Text] [Related]
19. Imaging of secretory tumors of the gastrointestinal tract.
ElGuindy YM; Javadi S; Menias CO; Jensen CT; Elsamaloty H; Elsayes KM
Abdom Radiol (NY); 2017 Apr; 42(4):1113-1131. PubMed ID: 27878636
[TBL] [Abstract][Full Text] [Related]
20. [Contributions of nuclear medicine to the diagnosis and follow-up of gastroenteropancreatic neuroendocrine tumors].
Casanovas MM
Endocrinol Nutr; 2009 Sep; 56 Suppl 3():14-9. PubMed ID: 20542215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
